

NEUmiRNA Therapeutics awarded \$650.000 grant from The Michael J. Fox Foundation to advance development of RNA Therapies for Parkinson's Disease

In collaboration with Motac Neuroscience and Center for RNA Medicine (Aalborg University)

[Copenhagen, 08/01/2023] - NEUmiRNA Therapeutics, a leading biotechnology company pioneering innovative RNA-based therapeutics, proudly announces the reception of a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) that will fund NEUmiRNA's groundbreaking work in advancing disease-modifying RNA therapies for Parkinson's disease (PD). The \$650.000 grant will propel the preclinical development of selected antisense oligonucleotides designed to selectively inhibit a micro-RNA at the center of PD pathophysiology.

In a synergistic industry-academia collaboration, NEUmiRNA will partner with Motac Neuroscience and the Center for RNA Medicine at Aalborg University to harness their collective expertise in developing cutting-edge RNA-based therapeutics. The synergy between NEUmiRNA's innovative approach, Motac Neuroscience's extensive experience in preclinical models for neurodegenerative diseases, and the research excellence of the Center for RNA Medicine at Aalborg University enables accelerated progress towards impactful treatments for PD.

Prof Janine Erler, grant PI and CEO of NEUmiRNA Therapeutics, commented, "This grant is a key milestone in our mission to revolutionize PD treatment. Receiving a grant from The Michael J. Fox Foundation will help translate groundbreaking discoveries in RNA biology into transformational therapies for PD patients."

NEUmiRNA's proprietary platform focuses on the development of RNA-based therapeutics that modulate disease pathways, presenting a novel avenue for treating neurodegenerative diseases rather than only alleviating symptoms.

The Michael J. Fox Foundation's funding support underscores the importance of collaborative innovation in driving progress toward new effective therapies for PD. This grant not only bolsters NEUmiRNA's research endeavors, but also reaffirms the Foundation's commitment to accelerating breakthroughs in Parkinson's research.

For media inquiries or further information, please contact:

Janine Erler, CEO
je@neumirna.com

